-
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Wednesday, March 9, 2022 - 7:38am | 275Read More...Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated severe hemophilia A patients aged 12 and above. The study met the primary endpoint, showing...
-
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
Monday, August 30, 2021 - 6:58am | 305Read More...A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary endpoints. Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) are jointly...
-
Mesoblast Spikes On Positive Cell Therapy Data in Back Pain Study
Thursday, February 11, 2021 - 6:41am | 411Read More...Positive results from Mesoblast Limited’s (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the company’s shares higher in the premarket after an announcement showing its stem cell treatment for chronic lower back pain is “safe,...
-
Adamas Pharmaceuticals Surges 30% Following Positive Phase 3 Results
Wednesday, December 23, 2015 - 9:49am | 184Read More...Shares of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) spiked higher by more than 30 percent early Wednesday after the company announced positive top-line Phase 3 results of ADS-5102 for patients with Parkinson's Disease. Adamas Pharmaceuticals said that results from its randomized, placebo-...
